KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $131.0 million.

  • Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) rose 262.67% to $131.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $131.0 million, marking a year-over-year increase of 262.67%. This contributed to the annual value of $131.0 million for FY2025, which is 262.67% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Shares Outstanding (Weighted Average) of $131.0 million as of Q4 2025, which was up 262.67% from $131.4 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $131.4 million in Q3 2025 and a low of $117.1 million during Q1 2021
  • Over the past 5 years, Alnylam Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $124.8 million (recorded in 2023), while the average stood at $124.4 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 384.22% in 2021 and then surged by 163.32% in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $118.5 million in 2021, then grew by 2.73% to $121.7 million in 2022, then grew by 2.64% to $124.9 million in 2023, then increased by 2.2% to $127.7 million in 2024, then grew by 2.63% to $131.0 million in 2025.
  • Its last three reported values are $131.0 million in Q4 2025, $131.4 million for Q3 2025, and $130.6 million during Q2 2025.